You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

December 26, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

New treatment for advanced melanoma approved by FDA

Accelerated approval has been granted by FDA to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients who have unresectable or metastatic melanoma not responding to treatment with other drugs. » More on this breakthrough therapy

FDA green lights combination antibiotic

FDA approved ceftolozane/tazobactam (Zerbaxa, Cubist Pharmaceuticals, Inc.) for the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by designated susceptible Gram-negative bacteria.» Details

Continuing Education

MTM essentials for smoking cessation

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to assist pharmacists in providing smoking cessation services for patients interested in quitting smoking..

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 14DT13-KCE28.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Lynparza approved to treat advanced ovarian cancer

FDA has approved olaparib (Lynparza, AstraZeneca) for the treatment of women with advanced ovarian cancer associated with defective BRCA genes, as determined by an FDA-approved test.
» Read more

 

RELATED ARTICLES

[BLOG]: Promising late-stage melanoma pipeline to evolve treatment algorithm

The latest FDA actions

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group